McGuirk, J.P.; Smith, J.R.; Divine, C.L.; Zuniga, M.; Weiss, M.L.
Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals 2015, 8, 196-220.
https://doi.org/10.3390/ph8020196
AMA Style
McGuirk JP, Smith JR, Divine CL, Zuniga M, Weiss ML.
Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals. 2015; 8(2):196-220.
https://doi.org/10.3390/ph8020196
Chicago/Turabian Style
McGuirk, Joseph P., J. Robert Smith, Clint L. Divine, Micheal Zuniga, and Mark L. Weiss.
2015. "Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease" Pharmaceuticals 8, no. 2: 196-220.
https://doi.org/10.3390/ph8020196
APA Style
McGuirk, J. P., Smith, J. R., Divine, C. L., Zuniga, M., & Weiss, M. L.
(2015). Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals, 8(2), 196-220.
https://doi.org/10.3390/ph8020196